Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine
12.10.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1.
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer. The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
1 Funding reference number FKZ 13GW0451A+B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nekome: Nazi Hunter Unmasks Hitler’s Hyenas in New Trailer Ahead of Steam Next Fest Demo15.10.2026 22:38:00 EEST | Press release
ProbablyMonsters, an independent video game company creating original AA games with AAA sensibilities, today unveiled a new trailer for Nekome: Nazi Hunterat the Galaxies Autumn Showcase, pulling back the curtain on the game’s villains, Hitler’s Hyenas. Alongside the new trailer, ProbablyMonsters announced that Nekome: Nazi Hunter will participate in October’s Steam Next Fest, giving players their first opportunity to experience this violent odyssey of revenge with a free PC demo available on Steam from October 19 through 26. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014661905/en/ “Nekome is Vano’s story: an exploration of a young Romani man who has had everything taken away from him, and who decides to pick up a knife and exact revenge on his family’s murderers,” said Jeronimo Barrera, ProbablyMonsters’ General Manager and Game Director. “Each of Hitler’s Hyenas brandishes their own form of evil and presents a new a
The Estée Lauder Companies Announces BEAUTY&YOU India 2026 Winners and Marks Five Years of Advancing Indian Beauty Entrepreneurship15.10.2026 18:58:00 EEST | Press release
The Estée Lauder Companies, in partnership with Nykaa and Startup India, an initiative of the Department for Promotion of Industry and Internal Trade (DPIIT) within India’s Ministry of Commerce and Industry, announced the winners of BEAUTY&YOU India 2026, the country’s leading beauty entrepreneurship program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015612324/en/ (L to R) BEAUTY&YOU India 2026 Winners Ajaykumar Mehta, Shriya Rambhia, and Dheer Rambhia, Directors, Goyam Green Tech (BREAKTHROUGH), Nirja Bhatt, Founder & CEO, Laani (GROW), Khatija Shabana, CEO, and Syed Mohammad Fouzan, Director, Boldpurity (IMAGINE), Rinzing Choden Bhutia, Founder, Agapi Sikkim (Visionary Women’s Award), and Pankti Sheth, Founder & Creative Director, De Icebreaker Creative Studio (DESIGN). For five years, BEAUTY&YOU India has discovered, supported, and accelerated India’s next generation of beauty entrepreneurs. Since launching in 202
BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration15.10.2026 18:00:00 EEST | Press release
BioLab Holdings announced today a new, larger mission with the launch of EmeraNova™, a new corporate identity that reflects a broader ambition to advance tissue restoration across specialties, healing phases, and care settings. The launch marks the company’s efforts to build a global platform focused on identifying promising technologies and accelerating their path into clinical practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015721831/en/ EmeraNova seeks partners around the world to bring promising technologies to market quickly and equip clinicians with advanced, effective solutions. EmeraNova represents a vision to pursue emerging (Emer) and new (Nova) technologies by building an expanding toolbox of tissue restoration solutions, world-class support, and ways to bring together expert voices and clinical insights that will help shape what comes next. The company’s roots in chronic wound care will inform its fut
Body of Waves , a New Artwork Only at teamLab Planets TOKYO, Unveiled15.10.2026 18:00:00 EEST | Press release
teamLab Planets TOKYO (hereinafter referred to as “teamLab Planets”) has unveiled Body of Waves, a new artwork in which visitors enter a soft sculpture with their entire bodies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014474897/en/ teamLab, Body of Waves, 2026, from the series Soft Black Hole - Your Body Becomes a Space that Influences Another Body, 2016-© teamLab *Shot in real space. No AI or CGI. In addition, Existence in the Flow Creates Vortices—where vortices are created behind people as they climb against the flow—and Waterfall of Ephemeral Crystals—where shining particles cascade down to create a waterfall of light particles—have also evolved, further expanding the experience at teamLab Planets. New Artwork Body of Waves As you walk, your feet sink. This force is transmitted to the large, soft and flexible sculpture spreading across the floor, causing the sculpture to physically deform. The force generated b
CTIBIOTECH™ Announces Strategic Partnership and MOU With Beijing Vital River to Advance Preclinical Biomedical Innovation in China15.10.2026 17:59:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today announces the signing of a Memorandum of Understanding (MOU) and strategic partnership with Beijing Vital River, a Charles River company and provider of research models and associated preclinical services in China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014604195/en/ CTIBIOTECH signs strategic partnership with Beijing Vital River, a Charles River Laboratories company for commercialization of human tissue bioassays and New Approach Methodologies (NAMs) in Popular Republic of China The agreement was signed in Shanghai during the Shanghai – Auvergne-Rhône-Alpes Economic Dialogue, organized by the Nouvel Institut Franco-Chinois (NIFC), as part of the official Auvergne-Rhône-Alpes Region delegation to China. This alliance is designed to bring CTIBIOTECH™'s unique p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom